Core Insights - 康方生物 has signed an exclusive commercialization rights agreement with 济川药业 for its self-developed drug 伊喜宁® (Inusimab injection) in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - 康方生物 will receive a total of RMB 80 million (including tax) as an upfront licensing fee and up to RMB 10 million (including tax) in milestone payments from 济川药业, which will handle the commercialization and sales of 伊喜宁® [1] Group 1 - 伊喜宁® is an innovative PCSK9 monoclonal antibody developed by 康方生物, approved for treatment of primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia (HeFH) and high cholesterol patients with atherosclerotic cardiovascular disease [2] - The drug has been included in the latest National Medical Insurance Directory and is highly recommended in the 2025 edition of expert consensus on managing cardiovascular risk related to blood lipids [2] - 伊喜宁® works by specifically binding to PCSK9 and blocking its interaction with LDL-R, thereby restoring LDL-R expression levels to enhance the clearance of LDL-C from plasma [2] Group 2 - Previous studies indicate that PCSK9 monoclonal antibody treatment significantly reduces cholesterol levels in patients already on statin therapy, lowering the risk of heart attacks and strokes [2] - Phase III clinical trials have shown that 伊喜宁® demonstrates excellent clinical efficacy across various risk stratifications, providing a new option for the clinical treatment of hypercholesterolemia and long-term control of cardiovascular risk [2]